Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Annovis Bio Inc chart...

About the Company

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.

CEO

Maria Maccecchini

Exchange

NEW YORK STOCK EXCHANGE INC.

Website

https://www.annovisbio.com/

$M

Total Revenue

8

Employees

$85M

Market Capitalization

-1.93

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ANVS News

Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?

1d ago, source: Zacks.com on MSN

Investors in Annovis Bio, Inc. ANVS need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2024 $5 Put had some of the highest implied ...

Annovis Bio to Shed Light on Neurodegenerative Diseases at International Conference

15d ago, source: Hosted on MSN

MALVERN, PA — Chester County-based Annovis Bio, Inc. (NYSE: ANVS) is set to make a significant impact at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024 ...

ANVS Oct 2024 5.000 put

21h ago, source: Yahoo Finance

Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

21d ago, source: Business Insider

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced ...

Annovis Bio Inc Ordinary Shares

29d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Annovis Bio Inc.

19d ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Annovis Bio Inc (ANVS)

20d ago, source: Investing

Annovis Bio, Inc. (ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III ...

Annovis Bio Inc Ordinary Shares ANVS

10d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...